Document Type : Original Research
Authors
- Seyed Abbas Tabatabaei Yazdi 1
- Masoomeh Safaei 2
- Mehran Gholamin 3
- Alireza Abdollahi 4
- Fatemeh Nili 2
- Mehdi Jabbari Nooghabi 5
- Kazem Anvari 6
- Majid Mojarrad 7
1 Department of Pathology, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran
4 Department of Pathology, School of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
5 Department of Statistics, Ferdowsi University of Mashhad, Mashhad, Iran
6 Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
7 Department of Medical Genetics, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract
Background & Objectives: Glioblastoma is the most common primary malignancy of the brain, the prognosis of which is poor. Immunotherapy with cancer/testis (CT) antigens is a novel therapeutic approach for glioblastoma. This study aimed to investigate the expression rate of MAGE-E1, GAGE, and SOX-6 in glioblastoma tumors using the immunohistochemistry (IHC) method.
Materials & Methods: Expression of MAGE-E1, GAGE, and SOX-6 were determined by IHC in 50 paraffin blocks of glioblastoma. The results were compared between variables including age, gender, tumor location, and Karnofsky performance status (Kps) score. Survival analysis was also performed.
Results: The expression levels of SOX-6, MAGE-E1, and GAGE were 82%, 78%, and 76%, respectively. The relationship between CT antigens and age, gender, and tumor location was not significant, while the association between MAGE-E1 expression and age was statistically significant (p =0.002). High expression levels of SOX-6 and MAGE-E1 were associated with low Kps scores (p =0.034 and p <0.001, respectively). Survival analysis showed that age >40 and Kps score p =0.005 and p =0.018, respectively). Expression of MAGE-E1 and GAGE was negatively associated with overall 2-year survival (p =0.001 and p =0.021, respectively).
Conclusion: The expression of all the three CT antigens, especially MAGE-E1 and SOX-6, was high in patients with glioblastoma. It can be concluded that these markers are ideal targets for immunotherapy in these patients. MAGE-E1 and SOX-6 can be considered as important markers in determining the prognosis of glioblastoma.
Highlights
- High expression of MAGE-E1, GAGE, and SOX6 in glioblastoma
- Association between high expression of MAGE-E1 and SOX6 and lower Kps score in glioblastoma
- Correlation between high expression of MAGE-E1 and GAGE and lower overall survival in glioblastoma
Keywords
Main Subjects
Introduction
There are 130 different types of brain tumors, among which glioblastoma is the most common. Glioblastoma comprises 15% of brain tumors (1). The incidence rate of glioblastoma increases with advancing age, with the highest incidence in individuals aged 75-84 years old (2). The average incidence rate of glioblastoma is approximately 3 per 100,000 population (3). The incidence of glioblastoma is higher in males, white race, and non-Hispanic ethnicity (4). Glioblastoma is an aggressive primary brain tumor in adults with a median survival of 15 months (5).
Despite treatment with surgery, radiotherapy, and chemotherapy, the prognosis of glioblastoma is poor (6). Age, performance status, and extent of tumor resection are the prognostic factors that are proposed as predictors of survival. However, the longest achievable survival in glioblastoma is still unclear (7). Currently, the standard treatment in patients with glioblastoma is surgical intervention, followed by local radiotherapy, as well as systemic chemotherapy with temozolomide, which is a DNA alkylating agent (8). According to the results of the European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC), prospective clinical trial 26981-22981/CE.3 and surgery followed by radiotherapy with adjuvant temozolomide increased the median survival of glioblastoma patients compared to surgical treatment followed by radiotherapy alone (27% vs. 10% in 2 years) (9).
In addition to the aforementioned treatment methods, immune gene therapy is suggested as a new method. Immune gene therapy employs different types of transport genes and has become promising in cancer treatment due to specificity in therapeutic effect based on the expressed protein(s) and low off-target effects. However, cancer cell-specific delivery of transgene(s) still poses some challenges that should be addressed (10).
Cancer/testis (CT) antigens are protein antigens expressed exclusively in healthy adult testicular germ cells, and they are aberrantly activated and expressed in various types of human cancers (11-14). A subset of CT antigens has been found to elicit spontaneous humoral and cell-mediated immune responses in cancer patients (15). It seems that these specified antigens would be desirable targets for immunotherapy.
Testicular cell antigens have protected immunological structure and lack human leukocyte antigen (HLA) class I; therefore, the expression of CT antigens could be immunogenic in other tissues. The rate of CT antigens expression is highly variable among different tumor types, but CT antigens are more often expressed in high-grade and late-stage cases (16, 17). Some CT antigens, including MAGE-E1, GAGE, and SOX-6 are expressed in a large number of brain tumors, which makes them potential targets for immunotherapy (18, 19). In this study, we aimed to evaluate the expression rate of MAGE-E1, SOX-6, and GAGE, as three important CT antigens, among glioblastoma patients using the immunohistochemical (IHC) technique.
Patient Selection
This study was conducted on patients with pathologic diagnosis of glioblastoma who underwent a surgical operation at the Oncology Centers of Qaem and Omid Hospitals in Mashhad, Iran from 2010 to 2012.
The sample size was determined to be 50 based on the findings of the study by Lee et al. and using the NCSS & PASS statistical software (20).
The inclusion criteria include availability of the paraffin blocks in the Pathology Department archives and having a confirmed diagnosis of glioblastoma by a pathologist. Samples with inappropriate quality for IHC assay for each marker, sample from patients who had undergone an initial treatment before surgery, and those with incomplete clinicopathologic information were excluded from the study.
Methods
Demographic information of the patients, including age, gender, tumor location, and phone number were collected. Fixed paraffin blocks of each patient were sectioned and stained by hematoxylin and eosin (H & E) and were reviewed by two pathologists. Then, the proper region was marked for IHC assay; 3-4 µ sections of each paraffin block were assessed by GAGE, SOX-6, and MAGE-E1 antibodies. The applied staining kits included MAGE-E1 (ab 121161; Abcam company, US), SOX-6 (ab30455; Abcam company, US), and GAGE (h00002543-b01p; Abnova, US; containing mouse monoclonal antibody).
The staining procedure included sectioning, preparing slides, fixation, dewaxing, antigen retrieval, endogen enzyme blocking, adding primary and secondary antibodies, stain improvement by diaminobenzidine, and hematoxylin, dehydration, and finally mounting.
The stained slides were examined by a Nikon microscope (Japan) with 100x and 400x magnification. Then, the percentage and intensity of cytoplasmic staining with MAGE-E1 and the percentage of nuclear staining with SOX6 and GAGE were evaluated and classified in all the slides.
Similar to the study by Guo et al. (21), samples were scored based on the percentage of the tumoral cells with MAGE-E1 positivity as follows: 0 (less than 1%), 1+ (1-10%), 2+ (11-50%), and 3+ (50%˂). We considered those scores as proportional scores.
MAGE-E1 cytoplasmic staining intensity was scored as follows: no staining (0), weak staining (1+), intermediate staining (2+), and severe staining (3+).
The final score for MAGE-E1 was calculated as combination of the intensity and proportional score as follows: negative (total score <2), 1+ (total score 2-3), 2+ (total score of 4), and 3+ (total score 5-6). A total score of negative/1+ was classified as low expression level for MAGE-E1 and a total score of 2+/3+ was classified as high expression level for MAGE-E1.
In terms of SOX-6, samples were categorized into four groups in terms of the percentage of expression of SOX-6 as follows; negative (less than 1%), 1+ or mild (1-30%), 2+ or moderate (30-70%), and 3+ or severe (more than 70%) based on the study by Ueda et al. (22).
In terms of GAGE, samples were categorized into four groups including negative (less than 1%), 1+ or mild (1-10%), 2+ or moderate (11-50%), and 3+ or severe (50%) based on the study by Gjerstorff on the extent of GAGE expression in lung tumors (23).
Based on the Kps score (24), the performance criterion of each patient was obtained and the survival rate was assessed in 24 months of follow-up. The expression levels of GAGE, SOX-6, and MAGE-E1 were compared among variables including gender, age, and location of the tumor.
Data Analysis
The association between Kps score and expression of the three antigens was investigated. Considering that the Kps score 80) in terms of Kps score. The relationship between the Kps score and the expression of the three CT antigens was evaluated. Due to the non-normal distribution of data, based on the Kruskal-Wallis test, the expression level of CT markers was compared among gender, tumor location, and Kps score categories using the Fisher's exact test. Survival analysis was performed using the Kaplan-Meier analysis during the time interval between surgery and 24 months of follow-up, and survival curves were drawn. The relationship between survival and other variables was studied. Data analyses were performed using the statistical package for social sciences SPSS 21 (SPSS Inc., Chicago, IL., USA). A P-value of less than 0.05 was considered as statistically significant.
Demographic Data
Of the 50 patients, 27 (54%) were male (M:F ratio=1.1). The mean age of the patients was 43.2±12.3 years old (age range: 20-69 years old). The majority of patients (28, 56%) were in the 40-60 years group.
The most common tumor location was the frontal lobe (36%) followed by temporal lobe (26%), parietal lob (16%), occipital lobe (8%), and other areas of the brain (14%).
Staining accuracy was investigated by comparing the stained samples with human testis tissue as a positive control (Figure 1).
Fig. 1. Nuclear staining of SOX10 (A), nuclear staining of GAGE (B) and cytoplasmic staining of MAGE-E1 (C) in normal testis tissue by immunohistochemistry (x100 magnification)
MAGE-E1 Staining
MAGE-E1 staining was negative (less than 1%) in 11 (22%) samples, +1 (1-10%) in 4 (8%) samples, +2 (11-50%) in 10 (20%) samples, and +3 (>50%) in 25 (50%) samples. Lack of staining was observed in 11 (22%) samples, while weak and intermediate staining was observed in 5 (10%) and 15 (30%) samples; severe staining was observed in 19 (38%) samples.
MAGE-E1 total scoring showed that 15 (30%) samples had low expression levels, while 35 (70%) samples obtained high expression levels.
SOX-6 Staining
SOX-6 staining was negative in 9 (18%) samples, mild (1+) in 11 (22%) samples, moderate (2+) in 14 (28%) samples, and severe (3+) in 16 (32%) samples.
GAGE Staining
GAGE staining was negative in 12 (24%) samples, mild in 26 (52%) samples, moderate in 7 (14%) samples, and severe in 5 (10%) samples.
Figure 2 shows nuclear staining for SOX-6, GAGE markers, and cytoplasmic staining for the MAGE-E1 marker in glioblastoma in the present study.
Fig. 2. Nuclear staining for SOX10 (A), GAGE (B) and cytoplasmic staining for MAGE-E1 in glioblastoma by immunohistochemistry (A and B: x100 magnification, C: x400 magnification)
Fig. 3. Kaplan-Meier curves showing correlation between overall survival and GAGE (A) and final score of MAGE-E1 (B). High expression l
The Expression Level of CT Antigens and Study Variables
Age
Fisher's exact test revealed a significant association between the percentage of expression and age (P˂0.001). This indicates that MAGE-E1 expression increased among older age groups. However, there was no significant correlation between GAGE and SOX-6 expression levels and age (P=0.918 and P=0.134, respectively) (Figure 3).
Gender
The Fisher’s exact test revealed no significant association between gender and expression levels of SOX-6, GAGE, and percentage/intensity of MAGE-E1 (P=0.490, P=0.305, P=0.288, and P=0.170, respectively).
Tumor Location
The Fisher’s exact test revealed no significant relationship between the location of the tumor and the expression levels of the CT antigens (P˃ 0.05).
The Relationship Between Kps Score and CT Antigens
Among the patients, 38 (76%) had Kps score <80, and 12 (24%) obtained Kps score ≥80. There was a significant difference between the expression of SOX-6 and MAGE-E1 and also the intensity of MAGE-E1 between Kps score groups (P=0.034, P<0.001, and P<0.001, respectively). The increased expression levels of SOX-6 and MAGE-E1 were related to lower Kps scores. No significant difference was found in terms of GAGE expression between Kps score groups (P=0.149) (Figure 3).
Survival Analysis
In the 24-month follow-up period of the 50 patients, 36 (72%) patients died and only 14 (28%) patients survived. The mean survival rate was 11.11 months. The overall 12-month survival rate was 46% and 24-month survival rate was 46%. A log-rank test showed a significant difference between survival and age, indicating that cases older than 40 years had shorter survival (P=0.005). Furthermore, a significant difference was observed in survival among patients with Kps score lower than 80 (P=0.018). However, the relationship between survival and gender and tumor location was not statistically significant (P=0.30 and P=0.512, respectively).
A log-rank test showed that the GAGE and MAGE-E1 expression levels, intensity, and the final score of MAGE-E1 significantly correlated with a low survival rate (P=0.021, P=0.001, P=0.001, and P=0.037, respectively). Nonetheless, the SOX-6 expression level was not significantly associated with survival (P=0.325).
Table 1. Expression of SOX6, GAGE and MAGE-E1 in different age groups in patients with glioblastoma
|
P-value |
Age groups )years) |
Cancer /Testis Antigens |
||||||
|
60-70 |
50-60 |
40-50 |
30-40 |
20-30 |
|
|||
|
0.918 |
2 |
3 |
3 |
2 |
5 |
-/1+ |
SOX6 expression |
|
|
2 |
11 |
11 |
8 |
3 |
2+/3+ |
|||
|
0.134 |
4 |
5 |
10 |
9 |
7 |
-/1+ |
GAGE expression |
|
|
0 |
9 |
4 |
1 |
1 |
2+/3+ |
|||
|
<0.001 |
0 |
1 |
1 |
3 |
4 |
-/1+ |
MAGE-E1 expression |
|
|
4 |
13 |
13 |
7 |
4 |
2+/3+ |
|||
Table 2. Associations between SOX6, GAGE and MAGE-E1 expression and clinical characteristics in patients with glioblastoma
|
P-value |
Tumor location |
P-value |
Gender |
|
Cancer/Testis Antigens |
||||||
|
Female |
Male |
||||||||||
|
Other |
Occipital |
Parietal |
Temporal |
Frontal |
|||||||
|
0.380 |
6 |
1 |
6 |
7 |
10 |
0.490 |
13 |
17 |
2+/3+ |
SOX6 expression |
|
|
1 |
3 |
2 |
6 |
8 |
10 |
10 |
-/1+ |
|
|||
|
0.203 |
3 |
2 |
0 |
3 |
4 |
0.305 |
3 |
9 |
2+/3+ |
GAGE expression |
|
|
4 |
2 |
8 |
10 |
14 |
20 |
18 |
-/1+ |
|
|||
|
0.893 |
6 |
2 |
4 |
10 |
13 |
0.288 |
13 |
22 |
2+/3+ |
MAGE-E1 expression |
|
|
1 |
2 |
4 |
3 |
5 |
10 |
5 |
-/1+ |
|
|||
Table 3. Associations between SOX6, GAGE and MAGE-E1 expression and Kps score in patients with glioblastoma
|
P-value |
Kps score |
Cancer /Testis Antigens |
||
|
<80 |
≥ 80 |
|||
|
0.034 |
23 |
7 |
2+/3+ |
SOX-6 expression |
|
15 |
5 |
-/1+ |
||
|
0.149 |
10 |
2 |
2+/3+ |
GAGE expression |
|
28 |
10 |
-/1+ |
||
|
<0.001 |
32 |
3 |
2+/3+ |
MAGE-E1 expression |
|
6 |
9 |
-/1+ |
||
|
0.001 |
31 |
3 |
Intermediate and strong |
MAGE-E1 intensity |
|
7 |
9 |
Weak and negative |
||
Table 4. Effect of clinicopathologic parameters on the mean of survival rate in patients with glioblastoma
|
P-value (log-rank) |
Mean and SD of survival (months) |
Clinicopathologic parameters |
||
|
0.005 |
10.7±1.2 |
40<= |
Age |
|
|
18.1±1.74 |
40> |
|||
|
0.512 |
12.7±1.64 |
Frontal |
Tumor location |
|
|
13.6±1.92 |
Temporal |
|||
|
14.8±3.24 |
Parietal |
|||
|
18.2±3 |
Occipital |
|||
|
10.14±2 |
Other sites |
|||
|
0.30 |
12.3±1.4 |
Male |
Gender |
|
|
14.6±1.5 |
Female |
|||
|
0.018 |
18.9±1.77 |
80<= |
Kps score |
|
|
11.6±1.15 |
80> |
|||
|
0.325 |
18.00±2.5 |
- |
SOX-6 expression |
|
|
12.63±2.2 |
1+ |
|||
|
12.29±1.8 |
2+ |
|||
|
11.7±1.7 |
3+ |
|||
|
0.021 |
17.7±2.17 |
- |
GAGE expression |
|
|
13.7±2.17 |
1+ |
|||
|
11.28±2.7 |
2+ |
|||
|
7.6±1.20 |
3+ |
|||
|
0.001 |
18.1±2.15 |
- |
MAGE-E1 expression |
|
|
21.2±1.4 |
1+ |
|||
|
15±2.4 |
2+ |
|||
|
9.4±1.09 |
3+ |
|||
|
0.001 |
18.1±2.15 |
- |
MAGE-E1 intensity |
|
|
19±2.3 |
Weak (1+) |
|||
|
14±1.9 |
Intermediate (2+) |
|||
|
8.6±1.14 |
Strong (3+) |
|||
|
0.037 |
18.6±1.7 |
˃2 |
MAGE-E1 final score |
|
|
10±0 |
2-3 |
|||
|
11.4±1.1 |
4-6 |
|||
In the current study, the mean age of glioblastoma patients was 43 years old and 56% of the patients were in the 40-60 years age group. In the studies carried out by Johnson et al. and Ueda et al., the mean age of the patients was 48 and 43 years old, respectively (22, 25). However, in the assessment of 449 patients with glioblastoma by Chandler et al., the mean age was reported to be 39.2 years old (26), which was lower than the mean age in our study. On the other hand, Scott et al. reported that the mean age of the patients with glioblastoma was 53 years old, which was higher than the mean age of the patients in our study (27).
Glioblastoma is more common among males (M:F ratio=1.5 to 1); but in our study, similar to the study reported by Johnson et al., the male to female ratio was almost equal to 1 (25).
In our study, the most common tumor locations were frontal and temporal lobes, which was similar to the findings of Ohgaki et al. (3). In contrast, Johnson et al. reported that the most common regions for glioblastoma were temporal and frontal lobes (25).
In the present study, MAGE-E1 positivity was observed in 78% of samples and the MAGE-E1 intensity was severe in 38% of the samples. The final score of MAGE-E1 was high (2+ and 3+) in 70% of glioblastoma cases in our study. Guo et al. (2003) reported an increased expression of MAGE-E1 by increasing histologic grade in glial tumors (21). Unlike some of the MAGE family members, including MAGE-A3, which do not have a high expression level in glioblastoma in some studies (28), the MAGE-E1 expression rate was high in our study. This finding was in line with the findings of the study carried out by He et al. (29). Therefore, MAGE-E1can be used as a target for immunotherapy.
In our study, GAGE expression was positive in 76% of glioblastoma samples, but 52% of the samples showed a mild expression level of GAGE (1-10% of tumor cells) and only 24% of the samples had an expression rate more than 10%. As a result, the expression of GAGE was somewhat different from the other two CT antigens (SOX6 expression in 60% of glioblastoma was more than 30%, and MAGE-E1 expression in 70% of tumors was more than 10%). Gjerstorff et al. (2006) evaluated GAGE expression in several types of cancer, including melanoma, breast, pulmonary, and liver, but not glioblastoma by polymerase chain reaction (PCR) and IHC methods. They observed heterogeneity within tumoral cells. They also observed apparent differences between GAGE antigen expression by IHC method and gene expression in some cancers; that gene expression was found higher than antigen expression (23). Furthermore, Scarcella et al. (1999) reported high levels of GAGE genes by RT-PCR (30). The findings of our study were in line with those of Gjerstorff et al. (23). Therefore, it could be hypothesized that the expression of the GAGE may vary at the cellular and gene levels in glioblastoma. Further studies are required to assess this finding.
Correlation between the expression rates of those three CT antigens with clinicopathologic criteria in our study was as follows: MAGE-E1 expression was increased by increasing age over 40 years, and survival rate was reduced among patients older than 40 years. In contrast to the findings of our study, such association was not reported by Guo et al. and He et al. (21, 29). We could not find a relationship between the clinicopathologic criteria and level of expression of SOX-6 and GAGE.
Our study revealed a significant correlation between high MAGE-E1 and SOX-6 level of expression and low Kps scores (Kps<80). This finding was similar to the findings of the study by Guo et al. (21).
In our study, the overall 12-month and 24-month survival rates were 46% and 28% for glioblastoma patients, respectively. These findings were in line with the findings of the study by Stupp (2009), who reported a two-year survival of 27% (31). In a review by Affronti et al., the survival rate for patients with glioblastoma was 69%, which was higher than the findings noted in our study, while the two-year survival rate was 29%, which was almost similar to the findings of our study (32).
Survival analysis in our study showed that aging, low Kps score, and high level of expression of MAGE-E1 and GAGE were associated with shorter survival rate. However, gender, tumor location, and SOX-6 expression had no significant association with survival rate. Correspondingly, Shinojima et al. (2004) reported a longer survival rate for females (33). In contrast to the findings of our study, Deltuva (2012) showed a lower survival rate for females (34).
The findings of our study revealed no relationship between the location of the tumor and prognosis. This finding was in contrast to the results of Jeremic et al. (1994), who reported a better prognosis for frontal lobe tumors (35).
We could not find any relationship between SOX-6 expression and survival rate.
As previously mentioned, SOX genes can cause malignant phenotype through cell proliferation, apoptosis, invasion, and cell migration (36). We found a significant association between the high expression of SOX-6 and Kps score. Therefore, SOX-6 could be considered as an important prognostic factor for glioblastoma.
By increasing the expression of MAGE-E1 and GAGE, the overall survival rate is diminished. These two antigens play an important role in resistance to chemotherapeutic agents. MAGE-E1 reduces cell differentiation (18) and GAGE plays a fundamental role in reducing apoptosis (37). The reason for this observation might be due to the increased expression of these two markers in our study.
Generally, the survival rate of patients with glioblastoma was short in our study and the mean survival rate was less than one year (mean survival: 11.11 months). However, some previous studies reported survival rate of 20 years and more (38, 39).
Identifying the level of expression of CT antigens in patients with glioblastoma may provide a deeper insight into some novel immunotherapy treatments. Our study found high level of expression in the three CT markers, particularly MAGE-E1 and SOX-6. Based on the current and previous findings, these markers would be excellent candidates and new modalities of treatment for glioblastoma.
The level of expression of all the three CT antigens, especially MAGE-E1 and SOX-6, were high in patients with glioblastoma. It can be concluded that these markers could be ideal targets for immunotherapy in glioblastoma. MAGE-E1 and SOX-6 expression were associated with lower Kps score and lower survival rate, which indicates their possible importance in determination of prognosis in glioblastoma.
This study has been funded by Mashhad University of Medical Sciences (project number: 3113)
The authors declare no conflict of interest.
- Young RM, Jamshidi A, Davis G, Sherman JH. Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med. 2015;3(9):121.
- Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncol. 2012;14(suppl 5):v1-v49. [DOI:10.1093/neuonc/nos218] [PMID] [PMCID]
- Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892-9. [DOI:10.1158/0008-5472.CAN-04-1337] [PMID]
- Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston‐Martin S. A population‐based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer. 2005;104(12):2798-806. [DOI:10.1002/cncr.21539] [PMID]
- Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 2012;108(1):11-27. [DOI:10.1007/s11060-011-0793-0] [PMID] [PMCID]
- Ahmadloo N, Kani AA, Mohammadianpanah M, Nasrolahi H, Omidvari S, Mosalaei A, et al. Treatment outcome and prognostic factors of adult glioblastoma multiforme. J Egypt Natl Canc Inst. 2013;25(1):21-30. [DOI:10.1016/j.jnci.2012.11.001] [PMID]
- Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien). 2009;151(11):1349-58. [DOI:10.1007/s00701-009-0387-1] [PMID]
- Mandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol. 2008;69(5):506-9; discussion 9. [DOI:10.1016/j.surneu.2007.03.043] [PMID]
- Wick W, van den Bent M, Vecht C, Brandes A, Lacombe D, Gorlia T, et al. EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. Eur J Cancer. 2012;10(1):20-6. [DOI:10.1016/S1359-6349(12)70006-X]
- Bakhtiar A, Sayyad M, Rosli R, Maruyama A, Chowdhury EH. Intracellular delivery of potential therapeutic genes: prospects in cancer gene therapy. Curr Gene Ther. 2014;14(4):247-57. [DOI:10.2174/1566523214666140612152730] [PMID]
- Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100(11):2014-21. [DOI:10.1111/j.1349-7006.2009.01303.x] [PMID]
- dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, et al. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 2000;60(6):1654-62.
- Old LJ. Cancer/testis (CT) antigens-a new link between gametogenesis and cancer. Cancer Immunity Archive. 2001;1(1):1.
- Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615-25. [DOI:10.1038/nrc1669] [PMID]
- Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4(1):1.
- Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K, et al. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer. 2000;83(4):493-7. [DOI:10.1054/bjoc.2000.1291] [PMID] [PMCID]
- Türeci Ö, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A. 1998;95(9):5211-6. [DOI:10.1073/pnas.95.9.5211] [PMID] [PMCID]
- Ghafouri-Fard S, Modarressi M-H. Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. 2011. [DOI:10.2217/imt.11.145] [PMID]
- Syed ON, Mandigo CE, Killory BD, Canoll P, Bruce JN. Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma. J Clin Neurosci. 2012;19(7):1016-21. [DOI:10.1016/j.jocn.2011.10.008] [PMID]
- Lee MH, Son EI, Kim E, Kim IS, Yim MB, Kim SP. Expression of cancer-testis genes in brain tumors. J Korean Neurosurg Soc. 2008;43(4):190-3. [DOI:10.3340/jkns.2008.43.4.190] [PMID] [PMCID]
- Guo L, Sang M, Liu Q, Fan X, Zhang X, Shan B. The expression and clinical significance of melanoma-associated antigen-A1, -A3 and -A11 in glioma. Oncology letters. 2013;6(1):55-62. [DOI:10.3892/ol.2013.1351] [PMID] [PMCID]
- Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, Toda M. Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene. 2004;23(7):1420-7. [DOI:10.1038/sj.onc.1207252] [PMID]
- Gjerstorff MF, Pohl M, Olsen KE, Ditzel HJ. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. BMC Cancer. 2013;13(1):466. [DOI:10.1186/1471-2407-13-466] [PMID] [PMCID]
- Péus D, Newcomb N, Hofer S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. BMC medical informatics and decision making. 2013;13(1):1. [DOI:10.1186/1472-6947-13-72] [PMID] [PMCID]
- Johnson P, Jaggon JR, Campbell J, Bruce C, Ferron-Boothe D, James K, et al. Profile of a Malignant Brain Tumour in Jamaica: An Eight-year Review, 2005 to 2012. West Indian Med J. 2015;64(4):372-5. [DOI:10.7727/wimj.2014.094] [PMID] [PMCID]
- Chandler KL, Prados MD, Malec M, Wilson CB. Long-term survival in patients with glioblastoma multiforme. Neurosurgery. 1993;32(5):716-20; discussion 20. [DOI:10.1097/00006123-199305000-00003]
- Scott J, Rewcastle N, Brasher P, Fulton D, MacKinnon J, Hamilton M, et al. Which glioblastoma multiforme patient will become a long‐term survivor? A population‐based study. Ann Neurol. 1999;46(2):183-8. https://doi.org/10.1002/1531-8249(199908)46:23.0.CO;2-7 [DOI:10.1002/1531-8249(199908)46:23.0.CO;2-7]
- Saikali S, Avril T, Collet B, Hamlat A, Bansard J-Y, Drenou B, et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapy. J Neurooncol. 2007;81(2):139-48. [DOI:10.1007/s11060-006-9220-3] [PMID]
- He SJ, Gu YY, Yu L, Luo B, Fan R, Lin WZ, et al. High expression and frequently humoral immune response of melanoma-associated antigen D4 in glioma. Int J Clin Exp Pathol. 2014;7(5):2350-60.
- Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res. 1999;5(2):335-41.
- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-66. [DOI:10.1016/S1470-2045(09)70025-7]
- Affronti ML, Heery CR, Herndon JE, Rich JN, Reardon DA, Desjardins A, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009;115(15):3501-11. [DOI:10.1002/cncr.24398] [PMID]
- Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K, et al. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg. 2004;101(2):219-26. [DOI:10.3171/jns.2004.101.2.0219] [PMID]
- Deltuva V, Bunevicius A, Jurkiene N, Kulakiene I, Tamasauskas A. Perioperative single photon emission computed tomography in predicting survival of malignant glioma patients. Oncology letters. 2012;4(4):739-44. [DOI:10.3892/ol.2012.812] [PMID] [PMCID]
- Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol. 1994;21(2):177-85. [DOI:10.1007/BF01052902] [PMID]
- Thu KL, Becker-Santos DD, Radulovich N, Pikor LA, Lam WL, Tsao MS. SOX15 and other SOX family members are important mediators of tumorigenesis in multiple cancer types. Oncoscience. 2014;1(5):326-35. [DOI:10.18632/oncoscience.46] [PMID] [PMCID]
- Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011;5(2):164-82. [DOI:10.1016/j.molonc.2011.02.001] [PMID] [PMCID]
- Kumar A, Deopujari C, Karmarkar V. A case of glioblastoma multiforme with long term survival: can we predict the outcome? Turkish neurosurgery. 2011;22(3):378-81. [DOI:10.5137/1019-5149.JTN.3638-10.3] [PMID]
- Sperduto CM, Chakravarti A, Aldape K, Burger P, Papermaster GB, Sperduto P. Twenty-year survival in glioblastoma: a case report and molecular profile. Int J Radiat Oncol Biol Phys. 2009;75(4):1162-5. [DOI:10.1016/j.ijrobp.2008.12.054] [PMID]
)